Surgery Websites
Hepatobiliary & Pancreatic Surgery »  Meet the Team »  Medical Oncology »  R. Kate Kelley, M.D.
R. Kate Kelley, M.D.

R. Kate Kelley, M.D.

  • Health Sciences Professor of Clinical Medicine,
  • Division of Hematology Oncology
  • Department of Medicine

Contact Information

(415) 353-9888 (appts)
(415) 353-9959 (fax)
1600 Divisadero St.,MZ Bldg A 
San Francisco, CA 94143-1770
Open Popup
Dr. Robin Kate Kelley is a gastrointestinal oncologist who specializes in cancers arising from the liver, including hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), and gallbladder carcinoma. Her research interests include developing clinical trials of new treatments and combination therapies for these cancers, including immunotherapy approaches as well as translational research to identify molecular and genetic biomarkers of response. Dr. Kelley graduated from the David Geffen School of Medicine at UCLA and completed a residency at UCLA, where she was chief resident in internal medicine. She then completed a fellowship in hematology and oncology at UCSF.

Dr. Kelley received an American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Merit Award in 2009, an ASCO Young Investigator Award in 2010, and the National Cancer Institute Cancer Clinical Investigator Team Leadership Award in 2014. She has authored numerous publications about treatments for advanced liver and bile duct cancers. She is involved in many organizations dedicated to improving the outcomes for patients with primary liver cancers, including National Comprehensive Cancer Network (NCCN) guideline panel for Liver Cancers, the National Cancer Institute Hepatobiliary Cancer Task Force, the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board, and the International Liver Cancer Association Education Committee.
  Dept or School    
  End Date    
  • University of California Los Angeles, Los Angeles, CA
  • Residency
  • Internal Medicine
  • 05/2005
  • University of California Los Angeles, Los Angeles, CA
  • M.D.
  • School of Medicine
  • 05/2002
  • Harvard College, Boston, MA
  • A.B.
  • Biochemical Sciences
  • 05/1997
  • University of California San Francisco, San Francisco, CA
  • Fellowship
  • Hematology/Oncology
  • 10/2009
  • University of California Los Angeles, Los Angeles, CA
  • Chief Residency
  • Internal Medicine
  • 06/2006
    • UCLA, Intern, 2002-05, Medicine
    • UCLA, Resident, 2005-06, Medicine
    • UCSF, Fellow, 2006-09, Hematology/Oncology
    • American Board of Internal Medicine
    • American Board of Internal Medicine: Medical Oncology - Subspecialty
    • UCSF Helen Diller Family Comprehensive Cancer Center
    • Anal Cancer
    • Colorectal Cancer
    • Hepatocellular Carcinoma (Liver Cancer)
    • Liver Metastases
    • Molecular Markers in Solid Tumors
    • Rectal Cancer
    Data provided by UCSF Profiles, powered by CTSI
    1. Zhu AX, Dayyani F, Yen CJ, Ren Z, Bai Y, Meng Z, Pan H, Dillon P, Mhatre SK, Gaillard VE, Hernandez S, Kelley RK, Sangro B. Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. Clin Cancer Res. 2022 08 15; 28(16):3537-3545. View in PubMed
    2. Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022 08; 23(8):995-1008. View in PubMed
    3. Llovet JM, Pinyol R, Kelley RK, El-Khoueiry A, Reeves HL, Wang XW, Gores GJ, Villanueva A. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma. Nat Cancer. 2022 04; 3(4):386-401. View in PubMed
    4. Freemantle N, Mollon P, Meyer T, Cheng AL, El-Khoueiry AB, Kelley RK, Baron AD, Benzaghou F, Mangeshkar M, Abou-Alfa GK. Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial. Eur J Cancer. 2022 06; 168:91-98. View in PubMed
    5. El-Khoueiry AB, Meyer T, Cheng AL, Rimassa L, Sen S, Milwee S, Kelley RK, Abou-Alfa GK. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer. 2022 Apr 09; 22(1):377. View in PubMed
    6. View All Publications


    Site Directory